Publicaciones en las que colabora con TERESA MORERA HERRERAS (19)

2023

  1. Efficacy of invasive and non-invasive methods for the treatment of Parkinson's disease: Nanodelivery and enriched environment

    International Review of Neurobiology (Academic Press Inc.), pp. 103-143

2022

  1. Motor cortico-nigral and cortico-entopeduncular information transmission and its modulation by buspirone in control and after dopaminergic denervation

    Frontiers in Pharmacology, Vol. 13

2021

  1. Origen y trayectoria del equipo docente para la Enseñanza Multidisciplinar Biosanitaria (IKAsasun)

    Revista Española de Educación Médica, Vol. 2, Núm. 3, pp. 55-64

  2. Study of tissue-specific reactive oxygen species formation by cell membrane microarrays for the characterization of bioactive compounds

    Membranes, Vol. 11, Núm. 12

  3. Trabajando la relación Universidad-sociedad. Abordaje multidisciplinar y difusión social

    FEM. Revista de la Fundación Educación Médica, Vol. 24, Núm. 1, pp. 36-41

2020

  1. Changes in Day/Night Activity in the 6-OHDA-Induced Experimental Model of Parkinson’s Disease: Exploring Prodromal Biomarkers

    Frontiers in Neuroscience, Vol. 14

  2. The Noradrenergic System in Parkinson’s Disease

    Frontiers in Pharmacology, Vol. 11

2019

  1. Acute L-DOPA administration reverses changes in firing pattern and low frequency oscillatory activity in the entopeduncular nucleus from long term L-DOPA treated 6-OHDA-lesioned rats

    Experimental Neurology, Vol. 322

  2. Effects of adult enriched environment on cognition, hippocampal-prefrontal plasticity and NMDAR subunit expression in MK-801-induced schizophrenia model

    European Neuropsychopharmacology, Vol. 29, Núm. 5, pp. 590-600

2018

  1. 5-HT2A receptors in the basal ganglia

    Receptors (Humana Press Inc.), pp. 273-310

2017

  1. Zergatik egiten digu alkoholak kalte?

    Ekaia: Euskal Herriko Unibertsitateko zientzi eta teknologi aldizkaria, Núm. 31, pp. 21-32

2016

  1. Buspirone requires the intact nigrostriatal pathway to reduce the activity of the subthalamic nucleus via 5-HT1A receptors

    Experimental Neurology, Vol. 277, pp. 35-45

  2. Cannabinoids and Motor Control of the Basal Ganglia: Therapeutic Potential in Movement Disorders

    CANNABINOIDS IN HEALTH AND DISEASE (INTECH EUROPE), pp. 59-92

  3. Chronic L-DOPA administration increases the firing rate but does not reverse enhanced slow frequency oscillatory activity and synchronization in substantia nigra pars reticulata neurons from 6-hydroxydopamine-lesioned rats

    Neurobiology of Disease, Vol. 89, pp. 88-100

2014

  1. Interaction between the 5-HT system and the basal ganglia: Functional implication and therapeutic perspective in Parkinson's disease

    Frontiers in Neural Circuits, Vol. 8, Núm. MAR

  2. Modulation of the subthalamic nucleus activity by serotonergic agents and fluoxetine administration

    Psychopharmacology, Vol. 231, Núm. 9, pp. 1913-1924

  3. Sistema serotonergikoaren eta gongoil basalen arteko elkarrekintza: inplikazio funtzionala eta terapiaren alderdia Parkinsonen gaixotasunean

    Ekaia: Euskal Herriko Unibertsitateko zientzi eta teknologi aldizkaria, Núm. 27, pp. 9-27

2013

  1. Kannabisaren terapiarako erabilera mugimenduaren asalduretan

    Ekaia: Euskal Herriko Unibertsitateko zientzi eta teknologi aldizkaria, Núm. 1, pp. 129-142

2012

  1. Endocannabinoid modulation of dopaminergic motor circuits

    Frontiers in Pharmacology, Vol. 3 JUN